[18F]-fluorodeoxyglucose scintigraphy in digestive cancer;Scintigraphie au [18F]-fluorodésoxyglucose en cancérologie digestive

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 4 SUPPL., 2001, Pages

  Montravers, F ^a   Grahek, D ^a   Kerrou, K ^a   De Beco, V ^a   Younsi, N ^a   Talbot, J N ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORINE;

BILE DUCT CARCINOMA; COLORECTAL CARCINOMA; CONFERENCE PAPER; DIAGNOSTIC IMAGING; ESOPHAGUS CARCINOMA; GASTROINTESTINAL CARCINOMA; HUMAN; IMAGE ANALYSIS; LIVER CARCINOMA; PANCREAS CARCINOMA; SCINTIGRAPHY; STOMACH CARCINOMA; DIGESTIVE SYSTEM TUMOR; REVIEW; SCINTISCANNING;

DEOXYGLUCOSE; DIGESTIVE SYSTEM NEOPLASMS; FLUORINE RADIOISOTOPES; HUMANS;

EID: 0034912291     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. FDG accumulation in tumor tissue
2. La gamma-caméra à détection de coïncidence: I. Principe, compromis, utilisation pour la scintigraphie conventionnelle
3. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation
4. The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: A PET study in liver metastases from colorectal carcinomas
5. Staging of primary colorectal carcinomas with fluorine-18 fluorideoxyglucose whole-body PET: Correlation with histopathologic and CT findings
6. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer lymphoma and melanoma
7. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
8. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
9. Staging recurrent metastatic colorectal carcinoma
10. The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
11. Positron emission tomography imaging of colorectal cancer
12. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
13. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver
14. Detection of liver metastases from pancreatic cancer using FDG PET
15. Additional value of whole-body positron emission tomography with fluorine-18-2-deoxy-D-glucose in recurrent colorectal cancer
16. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
17. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer
18. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy
19. F-18 FDG uptake in benign esophageal disease
20. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET
21. Positron emission tomography of esophageal carcinoma using (II)C-choline and (18)F-fluorodeoxyglucose: A novel method of preoperative lymph node staging
22. Accuracy of FDG-PET in gastric cancer: Preliminary experience
23. Increased F-18 FDG uptake in the stomach
24. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
25. Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma
26. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography
27. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours
28. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen
29. Evaluation of positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer
30. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease
31. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma
32. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases
33. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma
34. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies
35. 18-FDG positron emission tomography of the pancreas: Diagnostic benefit in the follow-up of pancreatic carcinoma